Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies
Status:
Not yet recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
This study is a single center, single arm, prospective, phase II clinical study to evaluate
the efficacy and safety of Venatoclax combined with reduced intensity conditioning regimen
allo-HSCT in the treatment of high-risk myeloid malignancies in the elderly patients.